HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Combination chemotherapy with intra-perioneal infusion of CDDP and continuous intravenous infusion of 5-FU for peritoneal metastasis in gastric cancer--analysis of long-term survivors].

Abstract
In order to evaluate the utility of combination chemotherapy with intra-peritoneal infusion of CDDP and continuous intravenous infusion of 5-FU, we performed this therapy in 23 primary gastric cancer patients with peritoneal metastasis. CDDP was administered intraperitoneally at a dose of 70 mg/m2 over 2 hours on day 1, and 5-FU was continuously administered intravenously at a dose of 700 mg/m2 for 5 consecutive days from day 1, respectively. This treatment was given twice. Median survival time with this treatment was 343 days, and the depth of invasion was selected as an independent prognostic factor according to multivariate analysis. Five patients (21.7%) have survived more than 3 years. Major toxicities were less than Grade 2 except for two patients with each anemia (Grade 3) and venous thrombosis (Grade 3), respectively. This regimen appears to be feasible and effective for gastric cancer patients with peritoneal metastases. Long term survival may be obtained in patients without adjacent organ invasion.
AuthorsHisataka Fujiwara, Masanori Terashima, Akinori Takagane, Kaoru Abe, Takashi Irinoda, Hitoshi Yonezawa, Tsutomu Nakaya, Kenichi Oyama, Masanori Takahashi, Kazuyoshi Saito
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 29 Issue 12 Pg. 2342-5 (Nov 2002) ISSN: 0385-0684 [Print] Japan
PMID12484070 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents
  • Cisplatin
  • Fluorouracil
Topics
  • Adult
  • Aged
  • Antimetabolites, Antineoplastic (administration & dosage)
  • Antineoplastic Agents (administration & dosage)
  • Cisplatin (administration & dosage)
  • Drug Therapy, Combination
  • Female
  • Fluorouracil (administration & dosage)
  • Humans
  • Infusions, Intravenous
  • Infusions, Parenteral
  • Male
  • Middle Aged
  • Peritoneal Neoplasms (drug therapy, mortality, secondary)
  • Peritonitis (drug therapy)
  • Stomach Neoplasms (drug therapy, mortality, pathology)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: